ACADIA Pharmaceuticals (NASDAQ:ACAD) dropped -6.44% or -2.41 points to trade at $34.99 per share. As per the latest trading data available, the net money flow stood at $3.63 million as the shares received $33.48 million in upticks and gave away $29.85 million in downticks. The final up/down ratio was at 1.12. On a weekly basis, the stock has seen a change of -6.47%.During the course of the session, the shares witnessed a block trade with an up/down ratio of 4.7. $5.21 million was the inflow in upticks and $1.11 million was the outflow in downticks. For the block trade, the net money flow was $4.1 million.
The stock has recorded a 20-day Moving Average of 6.69% and the 50-Day Moving Average is 3.15%. The company shares have dropped 12.86% in the past 52 Weeks. On July 15, 2015 The shares registered one year high of $51.99 and one year low was seen on February 9, 2016 at $16.64. The 50-day moving average is $34.28 and the 200 day moving average is recorded at $28.48. S&P 500 has rallied 1.93% during the last 52-weeks.
ACADIA Pharmaceuticals (NASDAQ:ACAD): The stock opened at $37.50 on Tuesday but the bulls could not build on the opening and the stock topped out at $37.52 for the day. The stock traded down to $34.32 during the day, due to lack of any buying support eventually closed down at $34.99 with a loss of -6.44% for the day. The stock had closed at $37.40 on the previous day. The total traded volume was 3,554,861 shares.
Currently the company Insiders own 22.42% of ACADIA Pharmaceuticals shares according to the proxy statements. Institutional Investors own 97.28% of ACADIA Pharmaceuticals shares. On the companys insider trading activities, The Securities and Exchange Commission has divulged that Baity Glenn, (EVP AND GC) of Acadia Pharmaceuticals Inc, had unloaded 7,000 shares at an average price of $20.8 in a transaction dated on March 2, 2016. The total value of the transaction was worth $145,600.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for the treatment of neurological and related central nervous system disorders. The Companys drug candidate NUPLAZID (pimavanserin) is under development for the treatment of Parkinsons disease psychosis, Alzheimers disease psychosis, Schizophrenia and Sleep disturbances. The Company is also conducting preclinical programs for alpha adrenergic agonists indicated for the treatment of chronic pain and muscarinic drugs for the treatment of glaucoma. NUPLAZID has an active ingredient pimavanserin, is a selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors that was discovered by the Company. The Company in collaboration with Allergan, has discovered and engaged in the development of small-molecule product candidates, such as alpha adrenergic agonists and muscarinic receptors.